文献速递系统性红斑狼疮

Iscalimab(CFZ533)治疗增殖性狼疮肾炎患者的疗效、药代动力学与安全性:一项随机、双盲、安慰剂对照的II期研究

Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study.
PubMed 文献 · RMD Open · 2025-08-14

这项II期随机双盲安慰剂对照多中心研究纳入57例活检证实的活动性增殖性狼疮肾炎患者,按2:1随机接受静脉iscalimab(10 mg/kg)或安慰剂24周联合标准治疗。第24周UPCR较基线相对改善iscalimab组63.1%、安慰剂组36.3%,组间比较显示iscalimab组UPCR较基线降低42.1%达统计学显著。Iscalimab总体耐受良好,但免疫抑制及合并症患者中出现少数严重感染和1例巨噬细胞活化综合征。

要点

  • 第24周UPCR较基线相对改善:iscalimab组63.1% vs 安慰剂组36.3%。
  • 第24周UPCR较基线组间比较:iscalimab组较安慰剂组降低42.1%,达统计学显著。
  • 严重不良事件:iscalimab组6例(15.4%)共7起 vs 安慰剂组3例(16.7%)共4起。

核心结论

  • Iscalimab在活动性狼疮肾炎患者中显著改善蛋白尿(UPCR)。
  • Iscalimab总体耐受良好,但免疫抑制及合并症患者中出现少数严重感染和1例巨噬细胞活化综合征。

研究设计与样本

  • II期、随机、双盲、安慰剂对照、多中心研究,纳入活检证实的活动性增殖性狼疮肾炎患者。
  • 患者按2:1随机接受静脉iscalimab(10 mg/kg)或安慰剂24周,均在狼疮肾炎标准治疗基础上加用。
  • 共随机57例(iscalimab组n=39,安慰剂组n=18),31例(54.4%)完成研究。
  • 主要疗效终点为第24周UPCR较基线的比值。
  • 安全性评估包括治疗期间及随访至49周的不良事件和严重不良事件。

主要发现

  • 第24周UPCR较基线相对改善:iscalimab组63.1% vs 安慰剂组36.3%。
  • 第24周UPCR较基线组间比较:iscalimab组较安慰剂组降低42.1%,达统计学显著。
  • 两治疗组大多数不良事件为轻至中度。
  • 严重不良事件:iscalimab组6例(15.4%)共7起 vs 安慰剂组3例(16.7%)共4起。

局限性

  • Iscalimab总体耐受良好,但免疫抑制及合并症患者中出现少数严重感染和1例巨噬细胞活化综合征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Iscalimab (CFZ533) is a novel, anti-CD40 monoclonal antibody. This study evaluated the efficacy, pharmacokinetics and safety of iscalimab versus placebo as add-on to standard-of-care (SoC) therapy in patients with biopsy-proven active proliferative lupus nephritis (LN). METHODS: This was a phase II, randomised, double-blind, placebo-controlled, multicentre study including patients with a diagnosis of systemic lupus erythematosus with active LN. Patients were randomly assigned (2:1) to receive either intravenous iscalimab (10 mg/kg) or placebo for 24 weeks on top of SoC for LN. The primary efficacy endpoint was the ratio from baseline in urinary protein-to-creatinine ratio (UPCR) at week 24. Safety assessments included adverse events (AEs) and serious AEs (SAEs) during treatment and follow-up up to 49 weeks. FINDINGS: Of the 57 patients (iscalimab, n=39; placebo, n=18) randomised, 31 (54.4%) completed the study. The primary efficacy endpoint was met: at week 24, the relative improvement from baseline in proteinuria (UPCR) was 63.1% and 36.3% in the iscalimab and placebo arms, respectively. UPCR to baseline at week 24 showed a statistically significant reduction of 42.1% in the iscalimab versus placebo arm. Most AEs were of mild to moderate severity in both treatment arms. Overall, seven SAEs were reported in six patients (15.4%) in the iscalimab arm versus four in three patients (16.7%) in the placebo arm. INTERPRETATION: Iscalimab showed a significant improvement in proteinuria (UPCR) in patients with active LN. Iscalimab was generally well tolerated with the exception of a few severe infections and one case of macrophage-activation syndrome in immunosuppressed and comorbid patients. TRIAL REGISTRATION NUMBER: NCT03610516.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Shen N, Weinmann-Menke J, Malvar A, et al. Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study. RMD Open. 2025. PMID: 40813108. doi:10.1136/rmdopen-2025-005557

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。